利用^99mTc直接法标记单克隆抗体及其HPLC分析

比较了２－巯基乙醇（２－ＭＥ）、二硫苏糖醇（ＤＴＴ）和抗坏血酸（ＡＡ）做为抗体还原剂进行９９ｍＴｃ直接标记ＩｇＧ的结果．以ＤＴＴ做为抗体还原剂进行了９９ｍＴｃ标记单克隆抗体３Ｈ１１及其Ｆａｂ片段研究．建立了分析鉴定９９ｍＴｃ标记抗体的ＨＰＬＣ方法．采用ＴＳＫ４０００ＳＷ为色谱性（１３μｍ,７．５ｍｍ×３００ｍｍ）和０．１ｍｏｌ／ＬＰＢＳ（ｐＨ７．０）为流动相,同时进行紫外检测和放射性检测,可快速地同时测定样品的蛋白质含量和标记率．     

鳜暴发流行病病毒性病原研究

患病鳜肾脏、脾脏、肝脏、心脏、鳃中发现二十面体病毒粒子,肾脏和脾脏是其感染主要器官．成熟病毒粒子直径１５０ｎｍ,核心球状,直径１０５ｎｍ．受感染细胞肿大,直径为正常细胞３～４倍,细胞核萎缩,为正常细胞核直径１／３．病毒粒子部分纯化后,经腹腔人工感染,第７天开始死亡,１０ｄ内死亡率为１００％,表现与池塘养殖状态相同症状,并在人工感染鳜肾和脾中电镜观察发现大量相同病毒粒子,命名为传染性脾肾坏死病毒（ｉｎｆｅｃｔｉｏｕｓｓｐｌｅｅｎａｎｄｋｉｄｎｅｙｎｅｃｒｏｓｉｓｖｉｒｕｓ,ＩＳＫＮＶ）．     

MRP1/CD9与肺癌的关系

肺癌发病率和死亡率增长较快,对人类健康和生命有很大威胁,早期发现早期治疗是诊治关键.MRP1/CD9是跨膜蛋白,属于TM4SF家族.与肿瘤恶性程度高低和转移有密切关系.检测肺癌组织中MRP1/CD9的表达水平有助于监测病情的进展、评估治疗效果、判定预后,为早期发现早期治疗提供指导意义.综述了MRP1/CD9的结构、功能、作用机制及与肺癌的关系的研究进展.     

我国新型肿瘤细胞治疗方法CIK的研究与应用现状

肿瘤的细胞治疗已经引起广泛关注,特别是各种肿瘤的免疫细胞治疗非常活跃。细胞因子诱导的杀伤细胞(CIK)治疗是近年来具有代表性的肿瘤细胞治疗方法,研究和应用进展迅速。为全面了解中国CIK的学术动态,利用中国医院知识仓库CHKD期刊全文库,以公开发表的论文为基础,进行现状分析。检索文献出现CIK的检索年限为1994,结束文献检索时间为2007年初,共检出相关文章148篇。将文献进行分析,通过已发表的文献介绍国内CIK研究与应用状况,并分析了CIK研究应用趋势及其展望。     

注射麻醉剂抑制小鼠EMT6乳腺肿瘤的生长

通过注射常规麻醉剂,可以降低患肿瘤生物个体新陈代谢强度,继而抑制其肿瘤生长及降低疼痛;观察了麻醉剂对移植性小鼠乳腺癌(EMT6)生长的抑制作用。通过对移植乳腺癌肿瘤小鼠的培养及给药实验,全面模拟人体生长肿瘤时的生理特征。在小鼠完成移植肿瘤细胞1周后,开始注射麻醉剂,同时对肿瘤生长及小鼠生理状况进行逐天监控;给药2周后处死小鼠并检测。实验发现,注射麻醉剂组小鼠肿瘤生长速度慢于实验对照组,肿瘤抑制率最高达18.5%。结果表明,注射麻醉剂可以延缓肿瘤生长,在乳腺癌治疗上具有可行性。     

血清CA19-9对良、恶性胆道疾病的诊断价值

目的:探讨血清糖类抗原CA19-9对良、恶性胆道疾病的诊断价值.方法:选取确诊的良、恶性胆道疾病患者114例,健康成年人49例,用全自动化学发光免疫分析仪检测血清CA19-9水平,并检测血清中的总胆红素(STB)、直接胆红素(CB)含量.结果:①胆道癌患者血清CA19-9水平明显高于正常对照组、胆囊炎和胆道结石患者(P<0.05);胆道结石黄疸组血清CA19-9水平明显高于无黄疸组、胆囊炎组和正常对照组(P<0.05),显著低于胆道癌患者(P<0.05).②血清CA19-9检测诊断胆道癌的敏感度、特异度和准确度分别是93.75%、66.33%和70.18%.③胆道结石黄疸组患者血清CA19-9水平与STB之间r=0.759(P<0.001),与CB之间r=0.775(P<0.001).结论:血清CA19-9检测是筛查胆道恶性疾病的灵敏指标,但对于伴有黄疸的血清CA19-9阳性患者,应进一步排除良性梗阻性疾病的可能.     

彩色多普勒超声对45例胡桃夹现象的诊断及支架植入术后的监测

目的:探讨彩色多普勒超声对胡桃夹现象患者的诊断意义、左肾静脉受压程度与临床表现之间的关系及对胡桃夹现象患者支架植入术后疗效的评价意义。方法:回顾分析45例胡桃夹现象患者的彩色多普勒超声表现,并将其与数字减影血管造影检查对照;按照临床表现将其分为3组:精索静脉曲张组、血尿组、蛋白尿组,分别测量左肾静脉受压狭窄部位(b)及受压扩张部位近端内径(a),扩张部位左肾静脉血流速度(Va)及受压部位血流速度(Vb),分析比较各组左肾静脉的受压程度;对其中行左肾静脉支架植入术的7例胡桃夹现象患者术后进行超声检查,测量上述指标并与其术前检查结果对比。结果:45例患者均见左肾静脉受压征象,受压部位前可见扩张,仰卧位时扩张部位内径(a)/受压部位内径(b)>3.0,受压部位血流速度(Vb)大于扩张部位血流速度(Va);各组间a/b值与Vb/Va值差异不具有统计学意义(P>0.05);行左肾静脉支架植入术治疗的7例胡桃夹现象患者术前与术后的b值、Vb值相比差异均有显著性(P<0.05)。结论:彩色多普勒超声诊断胡桃夹现象既方便又实用,可为精索静脉曲张、反复血尿、蛋白尿而无法用实验室检查确诊的患者提供有意义的临床指导,而且可作为胡桃夹现象患者支架植入术后疗效评估的一种手段。     

胰腺实性假乳头状瘤1例

1病例 患者,女,48岁.陶"腹部不适,发现胰头占位性病变2年,近期肿块增大1月"人院.病程中无腹痛、腹泻、发热等症状.查体:腹平软,无压痛及反跳痛,右下腹可扪及一肿物,大小约9 cm × cm,边界不清,活动可.既往无胰腺炎病史,无外伤史.甲胎蛋白(AFP)、癌胚抗原(CEA、CA19-9)及鳞状细胞癌抗原(SCC)均为阴性.     

Microplate chemiluminescence enzyme immunoassay for the quantitative evaluation of carbohydrate antigen 72-4 in human serum

A highly sensitive and specific microplate chemiluminescence enzyme immunoassay （CLEIA） was developed for the quantitative evaluation of carbohydrate antigen 72-4 （CA72-4） in human serum, using luminol-H2O2 catalyzed by horseradish peroxidase （HRP） as the chemiluminescence system. The simple and quick determination was accomplished through a sandwich reaction mode. Several physicochemical parameters of the immunoreaction, including incubation conditions, antibody coating conditions, dilution ratio of anti-CA72-4-HRP conjugate, and chemiluminescence reaction time, were studied and optimized. The proposed method exhibited a linear range of 0-200 U/mL with correlation coefficient and detection limit of 0.9995 and 0.18 U/mL, respectively. The inter-assay and intra-assay coefficients of variation （CV） were both less than 10%. The average recovery of two clinical sera with low and high concentration CA72-4 was 99.3% and 98.7%, respectively. Normal tumor markers, including AFP, CEA, CA24-2, CA19-9 and CA15-3, did not cross-react with each other. The method＇s stability was evaluated by assessing its analytical performance after storing the immunoreagents at 4℃ and 37℃ for 7 days. Little difference was found, indicating satisfactory stability of the method. The present method has been successfully applied to the detection of CA72-4 human serum, and showed a good correlation with the commercially available ELISA kit （r^2=0.9383）. This method showed great potential in the fabrication of diagnostic kit for CA72-4, and could be well used in diagnosis of cancer in clinical practice.     

Capsid modification of adeno-associated virus and tumor targeting gene therapy

Targeting is critical for successful tumor gene therapy. The adeno-associated virus （AAV） has aroused wide concern due to its excellent advantages over other viral vectors in gene therapy. AAV has a broad infection spectrum, which also results in poor specificity towards tissues or cells and low transduction efficiency. Therefore, it is imperative to improve target and transduction efficiency in AAV-mediated gene therapy. Up to now, researchers have developed many strategies to modify AAV capsids for im- proving targeting or retargeting only desired cells. These strategies include not only traditional chemical modification, phage display technology, modification of AAV capsid genome, chimeric vectors and so on, but also many novel strategies involved in marker rescue strategy, direct evolution of capsid proteins, direct display random peptides on AAV capsid, AAVP （AAV-Phage）, and etc. This review will summarize the advances of researches on the capsid modification of AAV to target malignant cells.